2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov
Wallach JD, Krystal JH, Ross JS, O’Malley S. Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. JAMA Psychiatry 2020, 77: 1081-1084. PMID: 32459295, PMCID: PMC7254444, DOI: 10.1001/jamapsychiatry.2020.1167.Peer-Reviewed Original ResearchMeSH KeywordsAcupuncture TherapyAlcohol DeterrentsAlcoholismChinaClinical Trials as TopicCross-Cultural ComparisonHerbal MedicineHumansPsychotropic DrugsRegistriesUnited States
2019
Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman A, White JD, Wei L, Johnson FK, Krystal JH. Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development. Methods In Molecular Biology 2019, 2011: 3-22. PMID: 31273690, PMCID: PMC6895673, DOI: 10.1007/978-1-4939-9554-7_1.Peer-Reviewed Original ResearchConceptsPreclinical researchAnimal modelsPsychiatric conditionsLower clinical success ratesClinical success rateCommon psychiatric conditionsPsychiatric clinical trialsClinical trialsNew pharmacotherapiesMore effective interventionsPreclinical workPsychiatric disordersPsychiatric pathophysiologyMental illnessSystematic reviewEffective interventionsAnimal experimentsDrug development processSuccess rateDrug developmentHuman psychopathologyPharmaceutical companiesPredictive validityLarge pharmaceutical companiesAnimals
2017
It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group
Krystal JH, Davis LL, Neylan TC, Raskind M, Schnurr PP, Stein MB, Vessicchio J, Shiner B, Gleason TD, Huang GD. It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group. Biological Psychiatry 2017, 82: e51-e59. PMID: 28454621, DOI: 10.1016/j.biopsych.2017.03.007.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsClinical Trials as TopicHumansPsychopharmacologyPsychotropic DrugsStress Disorders, Post-Traumatic
2011
Neuroimaging insights into the role of cortical GABA systems and the influence of nicotine on the recovery from alcohol dependence
Cosgrove KP, Esterlis I, Mason GF, Bois F, O’Malley S, Krystal JH. Neuroimaging insights into the role of cortical GABA systems and the influence of nicotine on the recovery from alcohol dependence. Neuropharmacology 2011, 60: 1318-1325. PMID: 21276806, PMCID: PMC3078950, DOI: 10.1016/j.neuropharm.2011.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismBrainClinical Trials as TopicDrug Evaluation, PreclinicalGamma-Aminobutyric AcidHumansNicotineNicotinic AgonistsRadionuclide ImagingReceptors, GABA-ASmokingConceptsAlcohol withdrawalTobacco smokingGABA levelsNeuronal functionNeuronal nicotinic acetylcholine receptorsAlcohol-dependent smokersCortical GABA systemGABA neuronal functionProlonged alcohol withdrawalInfluence of nicotineNicotinic acetylcholine receptorsAlcohol-dependent individualsEffects of alcoholPreclinical evidenceRole of alcoholGABA systemPreclinical modelsTobacco smokeErminio CostaBenzodiazepine receptorsAcetylcholine receptorsAlcohol dependenceSmokingPrimary actionClinical experiments
2008
Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting
Barch DM, Carter CS, Arnsten A, Buchanan RW, Cohen JD, Geyer M, Green MF, Krystal JH, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting. Schizophrenia Bulletin 2008, 35: 109-114. PMID: 19023126, PMCID: PMC2643950, DOI: 10.1093/schbul/sbn163.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCognition DisordersCognitive ScienceHumansNeurosciencesSchizophreniaConceptsFirst CNTRICS meetingCognitive neuroscienceCognitive Neuroscience Treatment ResearchPromising taskSchizophrenia (MATRICS) initiativeTreatment researchBroad domainsTaskSuch paradigmsNeuroscienceSpecific paradigmSpecific tasksRelevant paradigmConstructsParadigmLine surveyCognitionSpecial issueGoalNominationsDomainResearchInformationArticleTrials
2007
The NMDA receptor as a therapeutic target in major depressive disorder.
Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS & Neurological Disorders - Drug Targets 2007, 6: 101-15. PMID: 17430148, DOI: 10.2174/187152707780363267.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntidepressive AgentsClinical Trials as TopicDepressive Disorder, MajorExcitatory Amino Acid AntagonistsGlutamic AcidHumansReceptors, N-Methyl-D-AspartateConceptsMajor depressive disorderNMDA receptorsDepressive disorderNovel antidepressant medicationsCognitive side effectsPotential of drugsAntidepressant medicationAntidepressant propertiesSuch medicationsGlutamatergic neurotransmissionGlutamate receptorsPreclinical studiesPsychotomimetic propertiesSide effectsTherapeutic targetAnimal modelsUseful agentNeurotransmissionReceptorsLines of evidenceMedicationsDisordersDrugsCurrent knowledgeDepressionPsychiatric safety of ketamine in psychopharmacology research
Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O’Donnell E, Krystal JH, D’Souza D. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192: 253-260. PMID: 17458544, DOI: 10.1007/s00213-007-0706-2.Peer-Reviewed Original ResearchConceptsSubanesthetic dosesHealthy human subjectsKetamine administrationClinical research programHuman subjectsTest sessionsPsychotic spectrum disordersPsychiatric safetyResidual sequelaePlacebo infusionIntravenous infusionKetamine effectsPsychopharmacology studiesResultsFour hundredAdverse reactionsObjectiveTo reportHealthy subjectsStudy participationClinical investigationHealthy humansSide effectsKetamineInfusionDosesAdministration
2003
A time of promise, a time of promises: ethical issues in advancing psychopharmacological research
Roberts LW, Krystal J. A time of promise, a time of promises: ethical issues in advancing psychopharmacological research. Psychopharmacology 2003, 171: 1-5. PMID: 14615879, DOI: 10.1007/s00213-003-1704-7.Peer-Reviewed Original ResearchBiomedical ResearchClinical Trials as TopicHumansPatient SelectionPsychiatryPsychopharmacologyResearch SubjectsN-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability
Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 2003, 99: 79-94. PMID: 12804700, DOI: 10.1016/s0163-7258(03)00054-8.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingAlcoholismAnimalsClinical Trials as TopicDisease SusceptibilityEthanolHumansReceptors, N-Methyl-D-AspartateRewardRisk FactorsSubstance Withdrawal SyndromeConceptsGlutamatergic systemEthanol abuseGlutamate receptorsN-methyl-D-aspartate (NMDA) subtypePrimary excitatory neurotransmitterAspartate glutamate receptorsAction of ethanolEthanol withdrawalGlutamatergic agentsGlutamatergic functionExcitatory neurotransmitterTranslational neuroscience perspectiveGlutamate systemEthanol intoxicationBehavioral effectsEthanol contributeAlcoholismBrainReceptorsTreatmentAbuseN-methylSubtypesNeurotransmittersIntoxicationTreatment Models and Designs for Intervention Research During the Psychotic Prodrome
Kane JM, Krystal J, Correll CU. Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. Schizophrenia Bulletin 2003, 29: 747-756. PMID: 14989412, DOI: 10.1093/oxfordjournals.schbul.a007044.Peer-Reviewed Original ResearchConceptsPsychotic prodromePsychotic disordersEarly interventionSubsequent symptom severityTreatment modelOngoing intervention trialsSpecific symptom clustersTreatment refractorinessFunctional disabilityPatient selectionIntervention trialsFunctional outcomeProdromal symptomsDisease progressionNatural courseTarget symptomsSubsyndromal symptomsDifferent treatment modelsOutcome measuresProdromal populationTreatment responseProdromal stateTrial designSymptom clustersSymptom severity
1989
Rapid detoxification from opioid dependence
Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Rapid detoxification from opioid dependence. American Journal Of Psychiatry 1989, 146: 1349a-1349. PMID: 2675644, DOI: 10.1176/ajp.146.10.1349a.Peer-Reviewed Original Research